CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial [Video]

Approximately 30% of patients with acute myeloid leukemia (AML) have CD7-positive disease due to the expression of CD7 on leukemic blasts and malignant progenitor cells. Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses the findings of a Phase I clinical trial (NCT04938115) which investigated the safety and efficacy of CD-7 targeted CAR T-cell therapy in heavily pretreated pediatric and adult patients with AML who had a CD7 expression of at least 50%. Four weeks after CAR-T, 70% of patients achieved complete remission (CR), and the safety profile of the therapy was manageable. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.